{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T04:19:43Z","timestamp":1744777183770,"version":"3.40.4"},"reference-count":121,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"NATIONAL NATURAL SCIENCE FOUNDATION OF CHINA","doi-asserted-by":"crossref","award":["82074240","82074240","82074240","82074240"],"award-info":[{"award-number":["82074240","82074240","82074240","82074240"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Chinese Society of Traditional Chinese Medicine Project \u2013 Basic Research on Dominant Diseases in Hematology","award":["202169-004","202169-004"],"award-info":[{"award-number":["202169-004","202169-004"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-02232-9","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T09:41:42Z","timestamp":1744710102000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Research trends in essential thrombocythemia from 2001 to 2024: a bibliometric analysis"],"prefix":"10.1007","volume":"16","author":[{"given":"Yiming","family":"Pan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dejian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanqin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyan","family":"Lang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,15]]},"reference":[{"key":"2232_CR1","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, Rodeghiero F, D\u2019Amore ES, Randi ML, Bertozzi I, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011;29:3179\u201384. https:\/\/doi.org\/10.1200\/JCO.2010.34.5298.","journal-title":"J Clin Oncol"},{"key":"2232_CR2","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.hoc.2020.12.001","volume":"35","author":"D Tremblay","year":"2021","unstructured":"Tremblay D, Yacoub A, Hoffman R. Overview of myeloproliferative neoplasms: history, pathogenesis, diagnostic criteria, and complications. Hematol Oncol Clin N. 2021;35:159\u201376. https:\/\/doi.org\/10.1016\/j.hoc.2020.12.001.","journal-title":"Hematol Oncol Clin N"},{"key":"2232_CR3","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1182\/blood.V6.4.372.372","volume":"6","author":"W Dameshek","year":"1951","unstructured":"Dameshek W. Some speculations on the myeloproliferative syndromes. Blood. 1951;6:372\u20135.","journal-title":"Blood."},{"key":"2232_CR4","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1056\/NEJM197610212951702","volume":"295","author":"JW Adamson","year":"1976","unstructured":"Adamson JW, Fialkow PJ, Murphy S, Prchal JF, Steinmann L. Polycythemia vera: stem-cell and probable clonal origin of the disease. New Engl J Med. 1976;295:913\u20136. https:\/\/doi.org\/10.1056\/NEJM197610212951702.","journal-title":"New Engl J Med"},{"key":"2232_CR5","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1182\/blood.V58.5.916.916","volume":"58","author":"PJ Fialkow","year":"1981","unstructured":"Fialkow PJ, Faguet GB, Jacobson RJ, Vaidya K, Murphy S. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood. 1981;58:916\u20139.","journal-title":"Blood"},{"key":"2232_CR6","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1182\/blood.V51.2.189.189","volume":"51","author":"RJ Jacobson","year":"1978","unstructured":"Jacobson RJ, Salo A, Fialkow PJ. Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood. 1978;51:189\u201394.","journal-title":"Blood"},{"key":"2232_CR7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41408-017-0041-8","volume":"8","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Vannucchi AM, Barbui T. Essential thrombocythemia treatment algorithm 2018. Blood Cancer J. 2018;8:2. https:\/\/doi.org\/10.1038\/s41408-017-0041-8.","journal-title":"Blood Cancer J"},{"key":"2232_CR8","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s00428-022-03465-7","volume":"482","author":"S Prakash","year":"2023","unstructured":"Prakash S, Arber DA, Bueso-Ramos C, Hasserjian RP, Orazi A. Advances in myelodysplastic\/myeloproliferative neoplasms. Virchows Arch. 2023;482:69\u201383. https:\/\/doi.org\/10.1007\/s00428-022-03465-7.","journal-title":"Virchows Arch"},{"key":"2232_CR9","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.cca.2016.09.023","volume":"462","author":"N Matsumoto","year":"2016","unstructured":"Matsumoto N, Mori S, Hasegawa H, Sasaki D, Mori H, Tsuruda K, Imanishi D, Imaizumi Y, Hata T, Kaku N, et al. Simultaneous screening for JAK2 and calreticulin gene mutations in myeloproliferative neoplasms with high resolution melting. Clin Chim Acta. 2016;462:166\u201373. https:\/\/doi.org\/10.1016\/j.cca.2016.09.023.","journal-title":"Clin Chim Acta"},{"key":"2232_CR10","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14740\/jh1042","volume":"11","author":"Z McKinnell","year":"2022","unstructured":"McKinnell Z, Karel D, Tuerff D, Sh AM, Nassereddine S. Acute myeloid leukemia following myeloproliferative neoplasms: a review of what we know, what we do not know, and emerging treatment strategies. J Hematol. 2022;11:197\u2013209. https:\/\/doi.org\/10.14740\/jh1042.","journal-title":"J Hematol"},{"key":"2232_CR11","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1182\/blood-2017-08-802165","volume":"130","author":"G Finazzi","year":"2017","unstructured":"Finazzi G. Ruxolitinib in ET: not all MPN are equal. Blood. 2017;130:1873\u20134. https:\/\/doi.org\/10.1182\/blood-2017-08-802165.","journal-title":"Blood"},{"key":"2232_CR12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa043800","volume":"353","author":"CN Harrison","year":"2005","unstructured":"Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. New Engl J Med. 2005;353:33\u201345. https:\/\/doi.org\/10.1056\/NEJMoa043800.","journal-title":"New Engl J Med"},{"key":"2232_CR13","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1007\/s10903-018-0778-6","volume":"21","author":"M Khosa","year":"2019","unstructured":"Khosa M, Bhulani N, Ali AA, Singh J, Khosa F, Nasrullah M. Bibliometrics of fifty most-cited articles on the mental health of immigrants living in the United States. J Immigr Minor Healt. 2019;21:414\u201329. https:\/\/doi.org\/10.1007\/s10903-018-0778-6.","journal-title":"J Immigr Minor Healt"},{"key":"2232_CR14","doi-asserted-by":"publisher","first-page":"1306234","DOI":"10.3389\/fped.2023.1306234","volume":"11","author":"Z Song","year":"2023","unstructured":"Song Z, Jia G, Luo G, Han C, Zhang B, Wang X. Global research trends of Mycoplasma pneumoniae pneumonia in children: a bibliometric analysis. Front Pediatr. 2023;11:1306234. https:\/\/doi.org\/10.3389\/fped.2023.1306234.","journal-title":"Front Pediatr"},{"key":"2232_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci13050724","author":"S Facciorusso","year":"2023","unstructured":"Facciorusso S, Spina S, Reebye R, Turolla A, Calabro RS, Fiore P, Santamato A. Sensor-based rehabilitation neurological diseases: a bibliometric analysis of research trends. Brain Sci. 2023. https:\/\/doi.org\/10.3390\/brainsci13050724.","journal-title":"Brain Sci"},{"key":"2232_CR16","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1007\/s10238-023-01089-y","volume":"23","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Jia Z, Xia X, Wang J. Knowledge mapping of COVID-19 and autoimmune diseases: a visual and bibliometric analysis. Clin Exp Med. 2023;23:3549\u201364. https:\/\/doi.org\/10.1007\/s10238-023-01089-y.","journal-title":"Clin Exp Med"},{"key":"2232_CR17","doi-asserted-by":"publisher","first-page":"1226629","DOI":"10.3389\/fphar.2023.1226629","volume":"14","author":"X Deng","year":"2023","unstructured":"Deng X, Wang J, Lu C, Zhou Y, Shen L, Ge A, Fan H, Liu L. Updating the therapeutic role of ginsenosides in breast cancer: a bibliometrics study to an in-depth review. Front Pharmacol. 2023;14:1226629. https:\/\/doi.org\/10.3389\/fphar.2023.1226629.","journal-title":"Front Pharmacol"},{"key":"2232_CR18","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1017\/cts.2020.29","volume":"4","author":"F Yu","year":"2020","unstructured":"Yu F, Van AA, Patel T, Mani N, Carnegie A, Corbie-Smith GM, Carey T, Buse J, Dave G. Bibliometrics approach to evaluating the research impact of CTSAs: a pilot study. J Clin Transl Sci. 2020;4:336\u201344. https:\/\/doi.org\/10.1017\/cts.2020.29.","journal-title":"J Clin Transl Sci"},{"key":"2232_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2023.105300","volume":"152","author":"M Sabe","year":"2023","unstructured":"Sabe M, Sulstarova A, Chen C, Hyde J, Poulet E, Aleman A, Downar J, Brandt V, Mallet L, Sentissi O, et al. A century of research on neuromodulation interventions: a scientometric analysis of trends and knowledge maps. Neurosci Biobehav R. 2023;152: 105300. https:\/\/doi.org\/10.1016\/j.neubiorev.2023.105300.","journal-title":"Neurosci Biobehav R"},{"key":"2232_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2022.104608","volume":"136","author":"M Sabe","year":"2022","unstructured":"Sabe M, Pillinger T, Kaiser S, Chen C, Taipale H, Tanskanen A, Tiihonen J, Leucht S, Correll CU, Solmi M. Half a century of research on antipsychotics and schizophrenia: a scientometric study of hotspots, nodes, bursts, and trends. Neurosci Biobehav R. 2022;136: 104608. https:\/\/doi.org\/10.1016\/j.neubiorev.2022.104608.","journal-title":"Neurosci Biobehav R"},{"key":"2232_CR21","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.joi.2017.08.007","volume":"11","author":"M Aria","year":"2017","unstructured":"Aria M, Cuccurullo C. bibliometrix: an R-tool for comprehensive science mapping analysis. J Informetr. 2017;11:959\u201375.","journal-title":"J Informetr"},{"key":"2232_CR22","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1182\/blood-2005-03-1320","volume":"106","author":"AV Jones","year":"2005","unstructured":"Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, Score J, Seear R, Chase AJ, Grand FH, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005;106:2162\u20138. https:\/\/doi.org\/10.1182\/blood-2005-03-1320.","journal-title":"Blood"},{"key":"2232_CR23","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","volume":"123","author":"G Rotunno","year":"2014","unstructured":"Rotunno G, Mannarelli C, Guglielmelli P, Pacilli A, Pancrazzi A, Pieri L, Fanelli T, Bosi A, Vannucchi AM. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood. 2014;123:1552\u20135. https:\/\/doi.org\/10.1182\/blood-2013-11-538983.","journal-title":"Blood"},{"key":"2232_CR24","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1182\/blood-2015-03-635235","volume":"126","author":"M Deininger","year":"2015","unstructured":"Deininger M, Radich J, Burn TC, Huber R, Paranagama D, Verstovsek S. The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis. Blood. 2015;126:1551\u20134. https:\/\/doi.org\/10.1182\/blood-2015-03-635235.","journal-title":"Blood"},{"key":"2232_CR25","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1182\/blood.2019004596","volume":"136","author":"B Rocca","year":"2020","unstructured":"Rocca B, Tosetto A, Betti S, Soldati D, Petrucci G, Rossi E, Timillero A, Cavalca V, Porro B, Iurlo A, et al. A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia. Blood. 2020;136:171\u201382. https:\/\/doi.org\/10.1182\/blood.2019004596.","journal-title":"Blood"},{"key":"2232_CR26","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC. A gain-of-function mutation of JAK2 in myeloproliferative disorders. New Engl J Med. 2005;352:1779\u201390. https:\/\/doi.org\/10.1056\/NEJMoa051113.","journal-title":"New Engl J Med"},{"key":"2232_CR27","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New Engl J Med. 2012;366:787\u201398. https:\/\/doi.org\/10.1056\/NEJMoa1110556.","journal-title":"New Engl J Med"},{"key":"2232_CR28","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1056\/NEJMoa065202","volume":"356","author":"LM Scott","year":"2007","unstructured":"Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, Futreal PA, Erber WN, McMullin MF, Harrison CN, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. New Engl J Med. 2007;356:459\u201368. https:\/\/doi.org\/10.1056\/NEJMoa065202.","journal-title":"New Engl J Med"},{"key":"2232_CR29","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellstrom-Lindberg E, Tefferi A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937\u201351. https:\/\/doi.org\/10.1182\/blood-2009-03-209262.","journal-title":"Blood"},{"key":"2232_CR30","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387\u201397. https:\/\/doi.org\/10.1016\/j.ccr.2005.03.023.","journal-title":"Cancer Cell"},{"key":"2232_CR31","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1038\/sj.leu.2404816","volume":"21","author":"RA Mesa","year":"2007","unstructured":"Mesa RA, Camoriano JK, Geyer SM, Wu W, Kaufmann SH, Rivera CE, Erlichman C, Wright J, Pardanani A, Lasho T, et al. A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia. Leukemia. 2007;21:1964\u201370. https:\/\/doi.org\/10.1038\/sj.leu.2404816.","journal-title":"Leukemia"},{"key":"2232_CR32","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","volume":"363","author":"S Verstovsek","year":"2010","unstructured":"Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. New Engl J Med. 2010;363:1117\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1002028.","journal-title":"New Engl J Med"},{"key":"2232_CR33","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, Vannucchi AM, Mesa RA, Demory JL, Barosi G, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International working group for myelofibrosis research and treatment. Blood. 2009;113:2895\u2013901. https:\/\/doi.org\/10.1182\/blood-2008-07-170449.","journal-title":"Blood"},{"key":"2232_CR34","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1208500","volume":"368","author":"R Marchioli","year":"2013","unstructured":"Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, De Stefano V, Elli E, Iurlo A, Latagliata R, et al. Cardiovascular events and intensity of treatment in polycythemia vera. New Engl J Med. 2013;368:22\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1208500.","journal-title":"New Engl J Med"},{"key":"2232_CR35","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544.","journal-title":"Blood"},{"key":"2232_CR36","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan J, et al. The 5th edition of the World Health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022;36:1703\u201319. https:\/\/doi.org\/10.1038\/s41375-022-01613-1.","journal-title":"Leukemia."},{"key":"2232_CR37","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054\u201361. https:\/\/doi.org\/10.1016\/S0140-6736(05)71142-9.","journal-title":"Lancet"},{"key":"2232_CR38","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NC, Berg T, Gisslinger B, Pietra D, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. New Engl J Med. 2013;369:2379\u201390. https:\/\/doi.org\/10.1056\/NEJMoa1311347.","journal-title":"New Engl J Med"},{"key":"2232_CR39","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","volume":"369","author":"J Nangalia","year":"2013","unstructured":"Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, Avezov E, Li J, Kollmann K, Kent DG, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. New Engl J Med. 2013;369:2391\u2013405. https:\/\/doi.org\/10.1056\/NEJMoa1312542.","journal-title":"New Engl J Med"},{"key":"2232_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030270","volume":"3","author":"Y Pikman","year":"2006","unstructured":"Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, Cuker A, Wernig G, Moore S, Galinsky I, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. Plos Med. 2006;3: e270. https:\/\/doi.org\/10.1371\/journal.pmed.0030270.","journal-title":"Plos Med"},{"key":"2232_CR41","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C James","year":"2005","unstructured":"James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, Garcon L, Raslova H, Berger R, Bennaceur-Griscelli A, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144\u20138. https:\/\/doi.org\/10.1038\/nature03546.","journal-title":"Nature"},{"key":"2232_CR42","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41408-018-0054-y","volume":"8","author":"T Barbui","year":"2018","unstructured":"Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, Orazi A, Tefferi A. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018;8:15. https:\/\/doi.org\/10.1038\/s41408-018-0054-y.","journal-title":"Blood Cancer J"},{"key":"2232_CR43","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","volume":"379","author":"J Grinfeld","year":"2018","unstructured":"Grinfeld J, Nangalia J, Baxter EJ, Wedge DC, Angelopoulos N, Cantrill R, Godfrey AL, Papaemmanuil E, Gundem G, MacLean C, et al. Classification and personalized prognosis in myeloproliferative neoplasms. New Engl J Med. 2018;379:1416\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1716614.","journal-title":"New Engl J Med"},{"key":"2232_CR44","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","volume":"129","author":"W Vainchenker","year":"2017","unstructured":"Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2017;129:667\u201379. https:\/\/doi.org\/10.1182\/blood-2016-10-695940.","journal-title":"Blood"},{"key":"2232_CR45","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799\u2013807. https:\/\/doi.org\/10.1056\/NEJMoa1110557.","journal-title":"N Engl J Med"},{"key":"2232_CR46","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1056\/NEJMoa1409002","volume":"372","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Mesa R, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. New Engl J Med. 2015;372:426\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1409002.","journal-title":"New Engl J Med"},{"key":"2232_CR47","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, Hehlmann R, Hoffman R, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29:761\u201370. https:\/\/doi.org\/10.1200\/JCO.2010.31.8436.","journal-title":"J Clin Oncol"},{"key":"2232_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/ph15020160","author":"MS Bader","year":"2022","unstructured":"Bader MS, Meyer SC. JAK2 in myeloproliferative neoplasms: still a protagonist. Pharmaceuticals-Base. 2022. https:\/\/doi.org\/10.3390\/ph15020160.","journal-title":"Pharmaceuticals-Base."},{"key":"2232_CR49","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","volume":"124","author":"E Rumi","year":"2014","unstructured":"Rumi E, Pietra D, Pascutto C, Guglielmelli P, Martinez-Trillos A, Casetti I, Colomer D, Pieri L, Pratcorona M, Rotunno G, et al. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood. 2014;124:1062\u20139. https:\/\/doi.org\/10.1182\/blood-2014-05-578435.","journal-title":"Blood"},{"key":"2232_CR50","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1182\/blood-2014-02-554634","volume":"123","author":"R Rampal","year":"2014","unstructured":"Rampal R, Al-Shahrour F, Abdel-Wahab O, Patel JP, Brunel JP, Mermel CH, Bass AJ, Pretz J, Ahn J, Hricik T, et al. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood. 2014;123:e123\u201333. https:\/\/doi.org\/10.1182\/blood-2014-02-554634.","journal-title":"Blood"},{"key":"2232_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23094573","author":"E Morsia","year":"2022","unstructured":"Morsia E, Torre E, Poloni A, Olivieri A, Rupoli S. Molecular pathogenesis of myeloproliferative neoplasms: from molecular landscape to therapeutic implications. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23094573.","journal-title":"Int J Mol Sci"},{"key":"2232_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/cells8080854","author":"F Perner","year":"2019","unstructured":"Perner F, Perner C, Ernst T, Heidel FH. Roles of JAK2 in aging, inflammation, hematopoiesis and malignant transformation. Cells-Basel. 2019. https:\/\/doi.org\/10.3390\/cells8080854.","journal-title":"Cells-Basel"},{"key":"2232_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.637116","volume":"11","author":"D Cattaneo","year":"2021","unstructured":"Cattaneo D, Croci GA, Bucelli C, Tabano S, Cannone MG, Gaudioso G, Barbanti MC, Barbullushi K, Bianchi P, Fermo E, et al. Triple-negative essential thrombocythemia: clinical-pathological and molecular features. A single-center cohort study. Front Oncol. 2021;11: 637116. https:\/\/doi.org\/10.3389\/fonc.2021.637116.","journal-title":"Front Oncol"},{"key":"2232_CR54","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1182\/blood-2004-06-2375","volume":"105","author":"AM Ferraris","year":"2005","unstructured":"Ferraris AM, Mangerini R, Pujic N, Racchi O, Rapezzi D, Gallamini A, Casciaro S, Gaetani GF. High telomerase activity in granulocytes from clonal polycythemia vera and essential thrombocythemia. Blood. 2005;105:2138\u201340. https:\/\/doi.org\/10.1182\/blood-2004-06-2375.","journal-title":"Blood"},{"key":"2232_CR55","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1182\/blood-2018-01-791491","volume":"131","author":"F Passamonti","year":"2018","unstructured":"Passamonti F, Maffioli M. The role of JAK2 inhibitors in MPNs 7 years after approval. Blood. 2018;131:2426\u201335. https:\/\/doi.org\/10.1182\/blood-2018-01-791491.","journal-title":"Blood"},{"key":"2232_CR56","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/leu.2015.277","volume":"30","author":"D Pietra","year":"2016","unstructured":"Pietra D, Rumi E, Ferretti VV, Di Buduo CA, Milanesi C, Cavalloni C, Sant\u2019Antonio E, Abbonante V, Moccia F, Casetti IC, et al. Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia. 2016;30:431\u20138. https:\/\/doi.org\/10.1038\/leu.2015.277.","journal-title":"Leukemia"},{"key":"2232_CR57","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/bjh.16380","volume":"189","author":"A Tefferi","year":"2020","unstructured":"Tefferi A, Guglielmelli P, Lasho TL, Coltro G, Finke CM, Loscocco GG, Sordi B, Szuber N, Rotunno G, Pacilli A, et al. Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. Brit J Haematol. 2020;189:291\u2013302. https:\/\/doi.org\/10.1111\/bjh.16380.","journal-title":"Brit J Haematol"},{"key":"2232_CR58","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1038\/s41591-018-0081-z","volume":"24","author":"P Desai","year":"2018","unstructured":"Desai P, Mencia-Trinchant N, Savenkov O, Simon MS, Cheang G, Lee S, Samuel M, Ritchie EK, Guzman ML, Ballman KV, et al. Somatic mutations precede acute myeloid leukemia years before diagnosis. Nat Med. 2018;24:1015\u201323. https:\/\/doi.org\/10.1038\/s41591-018-0081-z.","journal-title":"Nat Med"},{"key":"2232_CR59","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/leu.2010.69","volume":"24","author":"A Tefferi","year":"2010","unstructured":"Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 2010;24:1128\u201338. https:\/\/doi.org\/10.1038\/leu.2010.69.","journal-title":"Leukemia"},{"key":"2232_CR60","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1182\/blood-2018-04-846220","volume":"132","author":"S Jacquelin","year":"2018","unstructured":"Jacquelin S, Straube J, Cooper L, Vu T, Song A, Bywater M, Baxter E, Heidecker M, Wackrow B, Porter A, et al. Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation. Blood. 2018;132:2707\u201321. https:\/\/doi.org\/10.1182\/blood-2018-04-846220.","journal-title":"Blood"},{"key":"2232_CR61","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000578","volume":"5","author":"SN Constantinescu","year":"2021","unstructured":"Constantinescu SN, Vainchenker W, Levy G, Papadopoulos N. Functional consequences of mutations in myeloproliferative neoplasms. Hemasphere. 2021;5: e578. https:\/\/doi.org\/10.1097\/HS9.0000000000000578.","journal-title":"Hemasphere"},{"key":"2232_CR62","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1080\/17474086.2018.1484280","volume":"11","author":"E Rumi","year":"2018","unstructured":"Rumi E, Sant\u2019Antonio E, Boveri E, Pietra D, Cavalloni C, Roncoroni E, Astori C, Arcaini L. Diagnosis and management of prefibrotic myelofibrosis. Expert Rev Hematol. 2018;11:537\u201345. https:\/\/doi.org\/10.1080\/17474086.2018.1484280.","journal-title":"Expert Rev Hematol"},{"key":"2232_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107363","volume":"208","author":"G Navarro","year":"2024","unstructured":"Navarro G, Gomez-Autet M, Morales P, Rebassa JB, Llinas DTC, Jagerovic N, Pardo L, Franco R. Homodimerization of CB(2) cannabinoid receptor triggered by a bivalent ligand enhances cellular signaling. Pharmacol Res. 2024;208: 107363. https:\/\/doi.org\/10.1016\/j.phrs.2024.107363.","journal-title":"Pharmacol Res"},{"key":"2232_CR64","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19938","author":"R Wang","year":"2024","unstructured":"Wang R, Shi Z, Zhang Y, Wei L, Duan M, Xiao M, Wang J, Chen S, Wang Q, Huang J, et al. Development and validation of a deep learning model for morphological assessment of myeloproliferative neoplasms using clinical data and digital pathology. Brit J Haematol. 2024. https:\/\/doi.org\/10.1111\/bjh.19938.","journal-title":"Brit J Haematol"},{"key":"2232_CR65","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1007\/s00432-022-04067-1","volume":"149","author":"L Zhang","year":"2023","unstructured":"Zhang L, Ye X, Luo S, Xu X, Wang S, Jin K, Zheng Y, Zhu X, Chen D, Jin J, et al. Clinical features and next-generation sequencing landscape of essential thrombocythemia, prefibrotic primary myelofibrosis, and overt fibrotic primary myelofibrosis: a Chinese monocentric retrospective study. J Cancer Res Clin. 2023;149:2383\u201392. https:\/\/doi.org\/10.1007\/s00432-022-04067-1.","journal-title":"J Cancer Res Clin"},{"key":"2232_CR66","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/cncr.22365","volume":"109","author":"RA Mesa","year":"2007","unstructured":"Mesa RA, Niblack J, Wadleigh M, Verstovsek S, Camoriano J, Barnes S, Tan AD, Atherton PJ, Sloan JA, Tefferi A. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer Am Cancer Soc. 2007;109:68\u201376. https:\/\/doi.org\/10.1002\/cncr.22365.","journal-title":"Cancer Am Cancer Soc"},{"key":"2232_CR67","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12657","volume":"6","author":"T Barbui","year":"2022","unstructured":"Barbui T, Carobbio A, De Stefano V. Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment. Res Pract Thromb Hae. 2022;6: e12657. https:\/\/doi.org\/10.1002\/rth2.12657.","journal-title":"Res Pract Thromb Hae"},{"key":"2232_CR68","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1182\/blood-2017-02-765032","volume":"130","author":"S Verstovsek","year":"2017","unstructured":"Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rumi E, Gattoni E, Pieri L, Zhen H, Granier M, Assad A, et al. Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results. Blood. 2017;130:1768\u201371. https:\/\/doi.org\/10.1182\/blood-2017-02-765032.","journal-title":"Blood"},{"key":"2232_CR69","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","volume":"123","author":"E Rumi","year":"2014","unstructured":"Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD, Them NC, Berg T, Elena C, Casetti IC, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2014;123:1544\u201351. https:\/\/doi.org\/10.1182\/blood-2013-11-539098.","journal-title":"Blood"},{"key":"2232_CR70","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1007\/s00277-020-04002-9","volume":"99","author":"CN Harrison","year":"2020","unstructured":"Harrison CN, Schaap N, Mesa RA. Management of myelofibrosis after ruxolitinib failure. Ann Hematol. 2020;99:1177\u201391. https:\/\/doi.org\/10.1007\/s00277-020-04002-9.","journal-title":"Ann Hematol"},{"key":"2232_CR71","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/ajh.26857","volume":"98","author":"A Tefferi","year":"2023","unstructured":"Tefferi A. Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98:801\u201321. https:\/\/doi.org\/10.1002\/ajh.26857.","journal-title":"Am J Hematol"},{"key":"2232_CR72","doi-asserted-by":"publisher","first-page":"82","DOI":"10.12688\/f1000research.13167.1","volume":"7","author":"W Vainchenker","year":"2018","unstructured":"Vainchenker W, Leroy E, Gilles L, Marty C, Plo I, Constantinescu SN. JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders. F1000Res. 2018;7:82. https:\/\/doi.org\/10.12688\/f1000research.13167.1.","journal-title":"F1000Res"},{"key":"2232_CR73","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1136\/jclinpath-2020-206570","volume":"74","author":"O Michail","year":"2021","unstructured":"Michail O, McCallion P, McGimpsey J, Hindley A, Greenfield G, McAllister R, Feerick J, Arnold C, Cross N, Cuthbert R, et al. Mutational profiling in suspected triple-negative essential thrombocythaemia using targeted next-generation sequencing in a real-world cohort. J Clin Pathol. 2021;74:808\u201311. https:\/\/doi.org\/10.1136\/jclinpath-2020-206570.","journal-title":"J Clin Pathol"},{"key":"2232_CR74","doi-asserted-by":"publisher","DOI":"10.15252\/embr.202152904","volume":"23","author":"D Tvorogov","year":"2022","unstructured":"Tvorogov D, Thompson-Peach C, Fosselteder J, Dottore M, Stomski F, Onnesha SA, Lim K, Moretti P, Pitson SM, Ross DM, et al. Targeting human CALR-mutated MPN progenitors with a neoepitope-directed monoclonal antibody. Embo Rep. 2022;23: e52904. https:\/\/doi.org\/10.15252\/embr.202152904.","journal-title":"Embo Rep"},{"key":"2232_CR75","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1002\/ajh.26171","volume":"96","author":"S Achyutuni","year":"2021","unstructured":"Achyutuni S, Nivarthi H, Majoros A, Hug E, Schueller C, Jia R, Varga C, Schuster M, Senekowitsch M, Tsiantoulas D, et al. Hematopoietic expression of a chimeric murine-human CALR oncoprotein allows the assessment of anti-CALR antibody immunotherapies in vivo. Am J Hematol. 2021;96:698\u2013707. https:\/\/doi.org\/10.1002\/ajh.26171.","journal-title":"Am J Hematol"},{"key":"2232_CR76","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.637420","volume":"11","author":"GJ Handlos","year":"2021","unstructured":"Handlos GJ, Holmstrom MO, Jorgensen NG, Klausen U, Weis-Banke SE, El FD, Schollkopf C, Clausen MB, Gjerdrum L, Breinholt MF, et al. Therapeutic cancer vaccination with a peptide derived from the calreticulin exon 9 mutations induces strong cellular immune responses in patients with CALR-mutant chronic myeloproliferative neoplasms. Front Oncol. 2021;11: 637420. https:\/\/doi.org\/10.3389\/fonc.2021.637420.","journal-title":"Front Oncol"},{"key":"2232_CR77","doi-asserted-by":"publisher","first-page":"eaba4380","DOI":"10.1126\/scitranslmed.aba4380","volume":"14","author":"M Gigoux","year":"2022","unstructured":"Gigoux M, Holmstrom MO, Zappasodi R, Park JJ, Pourpe S, Bozkus CC, Mangarin L, Redmond D, Verma S, Schad S, et al. Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine. Sci Transl Med. 2022;14:eaba4380. https:\/\/doi.org\/10.1126\/scitranslmed.aba4380.","journal-title":"Sci Transl Med."},{"key":"2232_CR78","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1158\/2159-8290.CD-18-1356","volume":"9","author":"BC Cimen","year":"2019","unstructured":"Cimen BC, Roudko V, Finnigan JP, Mascarenhas J, Hoffman R, Iancu-Rubin C, Bhardwaj N. Immune checkpoint blockade enhances shared neoantigen-induced T-cell immunity directed against mutated calreticulin in myeloproliferative neoplasms. Cancer Discov. 2019;9:1192\u2013207. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-1356.","journal-title":"Cancer Discov"},{"key":"2232_CR79","doi-asserted-by":"publisher","first-page":"5086","DOI":"10.1182\/bloodadvances.2021005491","volume":"5","author":"G Hobbs","year":"2021","unstructured":"Hobbs G, Cimen BC, Moshier E, Dougherty M, Bar-Natan M, Sandy L, Johnson K, Foster JE, Som T, Macrae M, et al. PD-1 inhibition in advanced myeloproliferative neoplasms. Blood Adv. 2021;5:5086\u201397. https:\/\/doi.org\/10.1182\/bloodadvances.2021005491.","journal-title":"Blood Adv"},{"key":"2232_CR80","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/ajh.27216","volume":"99","author":"A Tefferi","year":"2024","unstructured":"Tefferi A, Vannucchi AM, Barbui T. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management. Am J Hematol. 2024;99:697\u2013718. https:\/\/doi.org\/10.1002\/ajh.27216.","journal-title":"Am J Hematol"},{"key":"2232_CR81","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s40164-024-00555-x","volume":"13","author":"R Wang","year":"2024","unstructured":"Wang R, Tang LV, Hu Y. Genetic factors, risk prediction and AI application of thrombotic diseases. Exp Hematol Oncol. 2024;13:89. https:\/\/doi.org\/10.1186\/s40164-024-00555-x.","journal-title":"Exp Hematol Oncol"},{"key":"2232_CR82","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1182\/blood-2010-03-272179","volume":"116","author":"A Carobbio","year":"2010","unstructured":"Carobbio A, Finazzi G, Antonioli E, Vannucchi AM, Barosi G, Ruggeri M, Rodeghiero F, Delaini F, Rambaldi A, Barbui T. Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria. Blood. 2010;116:1051\u20135. https:\/\/doi.org\/10.1182\/blood-2010-03-272179.","journal-title":"Blood"},{"key":"2232_CR83","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1200\/JCO.2011.34.7542","volume":"29","author":"M Bjorkholm","year":"2011","unstructured":"Bjorkholm M, Derolf AR, Hultcrantz M, Kristinsson SY, Ekstrand C, Goldin LR, Andreasson B, Birgegard G, Linder O, Malm C, et al. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. J Clin Oncol. 2011;29:2410\u20135. https:\/\/doi.org\/10.1200\/JCO.2011.34.7542.","journal-title":"J Clin Oncol"},{"key":"2232_CR84","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1182\/hematology.2023000451","volume":"2023","author":"D Tremblay","year":"2023","unstructured":"Tremblay D. Cytoreduction for ET and PV: who, what, when, and how? Hematol-Am Soc Hemat. 2023;2023:660\u20136. https:\/\/doi.org\/10.1182\/hematology.2023000451.","journal-title":"Hematol-Am Soc Hemat"},{"key":"2232_CR85","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1007\/s12185-022-03380-2","volume":"116","author":"N Komatsu","year":"2022","unstructured":"Komatsu N, Hashimoto Y, Baba T, Otsuka M, Akimoto T, Fernandez J. Safety and efficacy of anagrelide in Japanese post-marketing surveillance, with subgroup analyses on the effect of previous cytoreductive therapies, age, and starting dose. Int J Hematol. 2022;116:570\u20138. https:\/\/doi.org\/10.1007\/s12185-022-03380-2.","journal-title":"Int J Hematol"},{"key":"2232_CR86","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41408-022-00609-5","volume":"12","author":"G Pandey","year":"2022","unstructured":"Pandey G, Kuykendall AT, Reuther GW. JAK2 inhibitor persistence in MPN: uncovering a central role of ERK activation. Blood Cancer J. 2022;12:13. https:\/\/doi.org\/10.1038\/s41408-022-00609-5.","journal-title":"Blood Cancer J"},{"key":"2232_CR87","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13236147","author":"MC Putti","year":"2021","unstructured":"Putti MC, Bertozzi I, Randi ML. Essential thrombocythemia in children and adolescents. Cancers. 2021. https:\/\/doi.org\/10.3390\/cancers13236147.","journal-title":"Cancers"},{"key":"2232_CR88","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.3324\/haematol.2009.019190","volume":"95","author":"F Palandri","year":"2010","unstructured":"Palandri F, Polverelli N, Ottaviani E, Castagnetti F, Baccarani M, Vianelli N. Long-term follow-up of essential thrombocythemia in young adults: treatment strategies, major thrombotic complications and pregnancy outcomes. a study of 76 patients. Haematologica. 2010;95:1038\u201340. https:\/\/doi.org\/10.3324\/haematol.2009.019190.","journal-title":"Haematologica."},{"key":"2232_CR89","doi-asserted-by":"publisher","DOI":"10.3390\/ph15030374","author":"A Marcuzzi","year":"2022","unstructured":"Marcuzzi A, Rimondi E, Melloni E, Gonelli A, Grasso AG, Barbi E, Maximova N. New applications of JAK\/STAT inhibitors in pediatrics: current use of ruxolitinib. Pharmaceuticals-Base. 2022. https:\/\/doi.org\/10.3390\/ph15030374.","journal-title":"Pharmaceuticals-Base"},{"key":"2232_CR90","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.3324\/haematol.2009.020412","volume":"95","author":"SY Kristinsson","year":"2010","unstructured":"Kristinsson SY, Landgren O, Samuelsson J, Bjorkholm M, Goldin LR. Autoimmunity and the risk of myeloproliferative neoplasms. Haematologica. 2010;95:1216\u201320. https:\/\/doi.org\/10.3324\/haematol.2009.020412.","journal-title":"Haematologica"},{"key":"2232_CR91","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22083850","author":"DJ Medina-Leyte","year":"2021","unstructured":"Medina-Leyte DJ, Zepeda-Garcia O, Dominguez-Perez M, Gonzalez-Garrido A, Villarreal-Molina T, Jacobo-Albavera L. Endothelial dysfunction, inflammation and coronary artery disease: potential biomarkers and promising therapeutical approaches. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22083850.","journal-title":"Int J Mol Sci"},{"key":"2232_CR92","doi-asserted-by":"publisher","DOI":"10.3390\/life13061420","author":"E Dri","year":"2023","unstructured":"Dri E, Lampas E, Lazaros G, Lazarou E, Theofilis P, Tsioufis C, Tousoulis D. Inflammatory mediators of endothelial dysfunction. Life-Basel. 2023. https:\/\/doi.org\/10.3390\/life13061420.","journal-title":"Life-Basel"},{"key":"2232_CR93","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222011170","author":"P Theofilis","year":"2021","unstructured":"Theofilis P, Sagris M, Antonopoulos AS, Oikonomou E, Tsioufis C, Tousoulis D. Inflammatory mediators of platelet activation: focus on atherosclerosis and COVID-19. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms222011170.","journal-title":"Int J Mol Sci"},{"key":"2232_CR94","doi-asserted-by":"publisher","DOI":"10.3390\/jcdd11070206","author":"N Katkenov","year":"2024","unstructured":"Katkenov N, Mukhatayev Z, Kozhakhmetov S, Sailybayeva A, Bekbossynova M, Kushugulova A. Systematic review on the role of IL-6 and IL-1beta in cardiovascular diseases. J Cardiovasc Dev Dis. 2024. https:\/\/doi.org\/10.3390\/jcdd11070206.","journal-title":"J Cardiovasc Dev Dis"},{"key":"2232_CR95","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.863846","volume":"9","author":"Y Zaid","year":"2022","unstructured":"Zaid Y, Merhi Y. Implication of platelets in immuno-thrombosis and thrombo-inflammation. Front Cardiovasc Med. 2022;9: 863846. https:\/\/doi.org\/10.3389\/fcvm.2022.863846.","journal-title":"Front Cardiovasc Med"},{"key":"2232_CR96","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13045-024-01562-5","volume":"17","author":"TR Haage","year":"2024","unstructured":"Haage TR, Charakopoulos E, Bhuria V, Baldauf CK, Korthals M, Handschuh J, Muller P, Li J, Harit K, Nishanth G, et al. Neutrophil-specific expression of JAK2-V617F or CALRmut induces distinct inflammatory profiles in myeloproliferative neoplasia. J Hematol Oncol. 2024;17:43. https:\/\/doi.org\/10.1186\/s13045-024-01562-5.","journal-title":"J Hematol Oncol"},{"key":"2232_CR97","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s40778-020-00177-z","volume":"6","author":"D Hormaechea-Agulla","year":"2020","unstructured":"Hormaechea-Agulla D, Le DT, King KY. Common sources of inflammation and their impact on hematopoietic stem cell biology. Curr Stem Cell Rep. 2020;6:96\u2013107. https:\/\/doi.org\/10.1007\/s40778-020-00177-z.","journal-title":"Curr Stem Cell Rep"},{"key":"2232_CR98","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1182\/blood.2023023105","volume":"144","author":"F Caiado","year":"2024","unstructured":"Caiado F, Manz MG. IL-1 in aging and pathologies of hematopoietic stem cells. Blood. 2024;144:368\u201377. https:\/\/doi.org\/10.1182\/blood.2023023105.","journal-title":"Blood"},{"key":"2232_CR99","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20201541","author":"F Caiado","year":"2021","unstructured":"Caiado F, Pietras EM, Manz MG. Inflammation as a regulator of hematopoietic stem cell function in disease, aging, and clonal selection. J Exp Med. 2021. https:\/\/doi.org\/10.1084\/jem.20201541.","journal-title":"J Exp Med"},{"key":"2232_CR100","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1182\/blood-2017-06-780882","volume":"130","author":"EM Pietras","year":"2017","unstructured":"Pietras EM. Inflammation: a key regulator of hematopoietic stem cell fate in health and disease. Blood. 2017;130:1693\u20138. https:\/\/doi.org\/10.1182\/blood-2017-06-780882.","journal-title":"Blood"},{"key":"2232_CR101","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.leukres.2012.10.020","volume":"37","author":"HC Hasselbalch","year":"2013","unstructured":"Hasselbalch HC. Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development? Leukemia Res. 2013;37:214\u201320. https:\/\/doi.org\/10.1016\/j.leukres.2012.10.020.","journal-title":"Leukemia Res."},{"key":"2232_CR102","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.freeradbiomed.2017.03.030","volume":"107","author":"J Cadet","year":"2017","unstructured":"Cadet J, Davies K. Oxidative DNA damage and repair: an introduction. Free Radic Bio Med. 2017;107:2\u201312. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2017.03.030.","journal-title":"Free Radic Bio Med"},{"key":"2232_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100711","volume":"42","author":"S Koschmieder","year":"2020","unstructured":"Koschmieder S, Chatain N. Role of inflammation in the biology of myeloproliferative neoplasms. Blood Rev. 2020;42: 100711. https:\/\/doi.org\/10.1016\/j.blre.2020.100711.","journal-title":"Blood Rev"},{"key":"2232_CR104","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.3324\/haematol.2022.281634","volume":"108","author":"H Gleitz","year":"2023","unstructured":"Gleitz H, Schneider RK. \u201cASXL1\u201d-erating inflammation and bone marrow fibrosis in myeloproliferative neoplasms. Haematologica. 2023;108:1203\u20134. https:\/\/doi.org\/10.3324\/haematol.2022.281634.","journal-title":"Haematologica"},{"key":"2232_CR105","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1182\/blood.2022016835","volume":"141","author":"F Caiado","year":"2023","unstructured":"Caiado F, Kovtonyuk LV, Gonullu NG, Fullin J, Boettcher S, Manz MG. Aging drives Tet2+\/- clonal hematopoiesis via IL-1 signaling. Blood. 2023;141:886\u2013903. https:\/\/doi.org\/10.1182\/blood.2022016835.","journal-title":"Blood"},{"key":"2232_CR106","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s44161-023-00281-3","volume":"2","author":"W Liu","year":"2023","unstructured":"Liu W, Yalcinkaya M, Maestre IF, Olszewska M, Ampomah PB, Heimlich JB, Wang R, Vela PS, Xiao T, Bick AG, et al. Blockade of IL-6 signaling alleviates atherosclerosis in Tet2-deficient clonal hematopoiesis. Nat Cardiovasc Res. 2023;2:572\u201386. https:\/\/doi.org\/10.1038\/s44161-023-00281-3.","journal-title":"Nat Cardiovasc Res"},{"key":"2232_CR107","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.yjmcc.2021.07.004","volume":"161","author":"CS Marnell","year":"2021","unstructured":"Marnell CS, Bick A, Natarajan P. Clonal hematopoiesis of indeterminate potential (CHIP): linking somatic mutations, hematopoiesis, chronic inflammation and cardiovascular disease. J Mol Cell Cardiol. 2021;161:98\u2013105. https:\/\/doi.org\/10.1016\/j.yjmcc.2021.07.004.","journal-title":"J Mol Cell Cardiol"},{"key":"2232_CR108","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.026154","volume":"11","author":"KD Min","year":"2022","unstructured":"Min KD, Polizio AH, Kour A, Thel MC, Walsh K. Experimental ASXL1-mediated clonal hematopoiesis promotes inflammation and accelerates heart failure. J Am Heart Assoc. 2022;11: e026154. https:\/\/doi.org\/10.1161\/JAHA.122.026154.","journal-title":"J Am Heart Assoc"},{"key":"2232_CR109","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13045-022-01282-8","volume":"15","author":"Y Tie","year":"2022","unstructured":"Tie Y, Tang F, Wei YQ, Wei XW. Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets. J Hematol Oncol. 2022;15:61. https:\/\/doi.org\/10.1186\/s13045-022-01282-8.","journal-title":"J Hematol Oncol"},{"key":"2232_CR110","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.772408","volume":"12","author":"V Camacho","year":"2021","unstructured":"Camacho V, Kuznetsova V, Welner RS. Inflammatory cytokines shape an altered immune response during myeloid malignancies. Front Immunol. 2021;12: 772408. https:\/\/doi.org\/10.3389\/fimmu.2021.772408.","journal-title":"Front Immunol"},{"key":"2232_CR111","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3389\/fimmu.2020.00147","volume":"11","author":"PE Rovatti","year":"2020","unstructured":"Rovatti PE, Gambacorta V, Lorentino F, Ciceri F, Vago L. Mechanisms of leukemia immune evasion and their role in relapse after haploidentical hematopoietic cell transplantation. Front Immunol. 2020;11:147. https:\/\/doi.org\/10.3389\/fimmu.2020.00147.","journal-title":"Front Immunol"},{"key":"2232_CR112","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1000226","volume":"7","author":"M Salio","year":"2009","unstructured":"Salio M, Cerundolo V. Linking inflammation to natural killer T cell activation. Plos Biol. 2009;7: e1000226. https:\/\/doi.org\/10.1371\/journal.pbio.1000226.","journal-title":"Plos Biol"},{"key":"2232_CR113","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms12010230","author":"A Vojdani","year":"2024","unstructured":"Vojdani A, Koksoy S, Vojdani E, Engelman M, Benzvi C, Lerner A. Natural killer cells and cytotoxic T cells: complementary partners against microorganisms and cancer. Microorganisms. 2024. https:\/\/doi.org\/10.3390\/microorganisms12010230.","journal-title":"Microorganisms"},{"key":"2232_CR114","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12964-023-01428-2","volume":"22","author":"A Barshidi","year":"2024","unstructured":"Barshidi A, Ardeshiri K, Ebrahimi F, Alian F, Shekarchi AA, Hojjat-Farsangi M, Jadidi-Niaragh F. The role of exhausted natural killer cells in the immunopathogenesis and treatment of leukemia. Cell Commun Signal. 2024;22:59. https:\/\/doi.org\/10.1186\/s12964-023-01428-2.","journal-title":"Cell Commun Signal"},{"key":"2232_CR115","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1007\/s00432-020-03430-4","volume":"147","author":"L Schrickel","year":"2021","unstructured":"Schrickel L, Heidel FH, Sadjadian P, Becker T, Kolatzki V, Hochhaus A, Griesshammer M, Wille K. Interferon alpha for essential thrombocythemia during 34 high-risk pregnancies: outcome and safety. J Cancer Res Clin. 2021;147:1481\u201391. https:\/\/doi.org\/10.1007\/s00432-020-03430-4.","journal-title":"J Cancer Res Clin"},{"key":"2232_CR116","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1182\/blood.2021012743","volume":"139","author":"J Mascarenhas","year":"2022","unstructured":"Mascarenhas J, Kosiorek HE, Prchal JT, Rambaldi A, Berenzon D, Yacoub A, Harrison CN, McMullin MF, Vannucchi AM, Ewing J, et al. A randomized phase 3 trial of interferon-alpha vs hydroxyurea in polycythemia vera and essential thrombocythemia. Blood. 2022;139:2931\u201341. https:\/\/doi.org\/10.1182\/blood.2021012743.","journal-title":"Blood"},{"key":"2232_CR117","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.lrr.2014.05.003","volume":"3","author":"ME Bjorn","year":"2014","unstructured":"Bjorn ME, de Stricker K, Kjaer L, Ellemann K, Hasselbalch HC. Combination therapy with interferon and JAK1-2 inhibitor is feasible: proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera. Leuk Res Rep. 2014;3:73\u20135. https:\/\/doi.org\/10.1016\/j.lrr.2014.05.003.","journal-title":"Leuk Res Rep"},{"key":"2232_CR118","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1182\/blood.2019000428","volume":"134","author":"A Yacoub","year":"2019","unstructured":"Yacoub A, Mascarenhas J, Kosiorek H, Prchal JT, Berenzon D, Baer MR, Ritchie E, Silver RT, Kessler C, Winton E, et al. Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. Blood. 2019;134:1498\u2013509. https:\/\/doi.org\/10.1182\/blood.2019000428.","journal-title":"Blood"},{"key":"2232_CR119","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1016\/S2352-3026(21)00343-4","volume":"9","author":"GL Mazza","year":"2022","unstructured":"Mazza GL, Mead-Harvey C, Mascarenhas J, Yacoub A, Kosiorek HE, Hoffman R, Dueck AC, Mesa RA. Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a: a post-hoc analysis of the MPN-RC 111 and 112 trials. Lancet Haematol. 2022;9:e38\u201348. https:\/\/doi.org\/10.1016\/S2352-3026(21)00343-4.","journal-title":"Lancet Haematol"},{"key":"2232_CR120","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1182\/blood.2020005563","volume":"137","author":"TN Rao","year":"2021","unstructured":"Rao TN, Hansen N, Stetka J, Luque PD, Kalmer M, Hilfiker J, Endele M, Ahmed N, Kubovcakova L, Rybarikova M, et al. JAK2-V617F and interferon-alpha induce megakaryocyte-biased stem cells characterized by decreased long-term functionality. Blood. 2021;137:2139\u201351. https:\/\/doi.org\/10.1182\/blood.2020005563.","journal-title":"Blood"},{"key":"2232_CR121","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1182\/blood.2023020270","volume":"143","author":"M Usart","year":"2024","unstructured":"Usart M, Stetka J, Luque PD, Hansen N, Kimmerlin Q, Almeida FT, Lock M, Kubovcakova L, Karjalainen R, Hao-Shen H, et al. Loss of Dnmt3a increases self-renewal and resistance to pegIFN-alpha in JAK2-V617F-positive myeloproliferative neoplasms. Blood. 2024;143:2490\u2013503. https:\/\/doi.org\/10.1182\/blood.2023020270.","journal-title":"Blood"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02232-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-02232-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02232-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T09:41:44Z","timestamp":1744710104000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-02232-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,15]]},"references-count":121,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2232"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-02232-9","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,15]]},"assertion":[{"value":"29 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"528"}}